Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Eur Urol. 2020 Mar 4;78(3):387–399. doi: 10.1016/j.eururo.2020.02.012

Fig. 1 –

Fig. 1 –

PRISMA flowchart of bladder-preserving treatments for recurrent non–muscle-invasive bladder cancer following intravesical BCG. BCG = bacillus Calmette-Guérin; PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses.